LTP

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

Retrieved on: 
Monday, March 18, 2024
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Conference, Disease, Patient, LTP, Hereditary angioedema, HAE, Quality of life, Anxiety, University, KALV, Return, Treatment, Quality, Asthma, Pharmaceutical industry

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between the time to attack treatment and the effects delays in treatment have on clinical outcomes of people living with hereditary angioedema (HAE) at the 2024 HAEi Regional Conference Americas that took place in Panama City, Panama.
  • “These data show once again that people living with HAE still face challenges in following established guidelines for treating their attacks,” said Ben Palleiko, Chief Executive Officer of KalVista.
  • “Even short treatment delays can lead to worse clinical outcomes, and despite efficacious on-demand treatments, the fact that they need to be injected results in barriers which lead to significant underuse and resultant overuse of long-term prophylaxis.
  • (Poster Presentation)
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Maeve O’Connor, Allergy, Asthma, & Immunology Relief of Charlotte, Charlotte, NC, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users

EQS-News: Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
Wednesday, March 13, 2024
Neurotoxicity, Learning, Myenteric plexus, Conference, Penile spines, Therapy, Memory, LTP, DSM-IV codes, Poster, Science, IND, Dendrite, Pharmaceutical industry

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024

Retrieved on: 
Friday, March 8, 2024
Neurotoxicity, Learning, Myenteric plexus, Conference, Penile spines, Therapy, Memory, LTP, DSM-IV codes, Poster, Science, IND, Dendrite, Pharmaceutical industry

These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.

Key Points: 
  • These new findings strongly support previous studies where GAL-201 was characterized as a promising development candidate for the treatment of AD ( Russ et.
  • The data was presented this week at the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders ( AD/PD™ 2024: advances in science and therapy ).
  • “The positive results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.
  • Furthermore, they validate that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease, and not the deposited forms of Aβ.

Promising Results: TGR-63 Enhances Memory in Alzheimer's Mouse Model

Retrieved on: 
Wednesday, February 28, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Science, Acquisition, Neuropharmacology, Morris water navigation task, Dementia, Neuroscience, MWM, Amnesia, IGC, Spatial navigation, Deficit spending, Peptide, Memory, Spatial memory, Patient, LTP, Agitation, Mouse

The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.

Key Points: 
  • The data demonstrated enhanced memory function in an Alzheimer's mouse model, including improved memory acquisition, consolidation, and retrieval.
  • Ram Mukunda, CEO, commented, "These results underscore the efficacy of TGR-63 in enhancing spatial memory function in an Alzheimer's disease model, offering promising implications for potential therapeutic interventions in Alzheimer's and related neurodegenerative conditions.
  • The improvements in memory acquisition, consolidation, spatial memory formation, and retrieval highlight its potential in addressing cognitive impairment in Alzheimer's Disease.
  • The NOR Test, a cornerstone of preclinical research, evaluates recognition memory, a component of declarative memory responsible for recognizing previously encountered stimuli.

KalVista Pharmaceuticals Presents Data on Unmet Needs in HAE from a Patient Perspective at the 2024 American Academy of Allergy, Asthma & Immunology Annual Meeting

Retrieved on: 
Tuesday, February 27, 2024
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Anxiety, Division, AAAAI, University of Toronto, Hospital, Return, Annual general meeting, Safety, Howard University Hospital, University, HAE, Quality of life, Hereditary angioedema, Patient, University of California, LTP, KALV, Impact, American Academy, Campbelltown Hospital

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.

Key Points: 
  • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting that took place in Washington, DC.
  • The following presentations occurred at AAAAI 2024:
    Characteristics of Hereditary Angioedema Attacks Among Long-Term Prophylaxis Users: Bob Geng, Allergy and Immunology, University of California, San Diego, California, United States (Poster Presentation)
    Among HAE patients who had treated a recent attack, the location and duration of the most recent attacks were similar between long-term prophylaxis (LTP) and on-demand only users
    Earlier on-demand treatment was associated with a shorter attack duration, regardless of LTP use
    Delayed On-demand Treatment of Hereditary Angioedema Attacks: Patient Perceptions and Associated Barriers: Sandra Christiansen, University of California San Diego, La Jolla, CA, United States (Poster Presentation)
    The most common barriers to earlier treatment were uncertainty if attack was real, thinking the attack would be mild, and wanting to save treatment for a severe attack
    Anxiety Associated with On-Demand Treatment for Hereditary Angioedema (HAE) Attacks: James Wedner, Washington University School of Medicine, St Louis, MO, United States (Poster Presentation)
    Both adults and adolescents with HAE reported moderate to extreme anxiety when anticipating use of parenteral on-demand treatment, irrespective of use of on-demand only or on-demand plus LTP
    The results of this study highlighted the association between delayed treatment and treatment-related anxiety, with a higher proportion of patients who delayed treatment experiencing moderate to extreme anxiety
    Anxiety Associated with Refilling On-demand Therapy for HAE Attacks Contributes to Treatment Delay and Non-Treatment: Autumn Burnette, Division of Allergy and Immunology, Howard University Hospital, Washington, DC, United States (Poster Presentation)
    Anxiety associated with not being able to refill on-demand treatment quickly impacted treatment decisions, which contributed to treatment delay or resulted in non-treatment of HAE attacks
    Characterizing the Negative Impact of Delayed On-Demand Treatment of HAE Attacks: Princess Ogbogu, Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States (Poster Presentation)
    The Impact of On-demand Treatment on Quality of Life of People with HAE: Paula Busse, Department of Medicine, Division of Clinical Immunology, Mount Sinai, New York, United States (Poster Presentation)
    Characterizing the Perspective of Patients With HAE on Prophylactic Treatment: Stephen Betschel, Division of Allergy and Immunology, Department of Medicine, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada (Poster Presentation)
    Only 35% of LTP patients always carried on-demand treatment when away from home, while 43% of prophylaxis patients cited avoiding potential triggers as a reason for not carrying on-demand treatment at all times
    Treatment Patterns of Patients Requiring Redosing of an On-demand Treatment After the Return of an HAE Attack: Constance Katelaris, Department of Medicine, Campbelltown Hospital and Western Sydney University, Sydney, NSW, Australia (Poster Presentation)
    “The results of these surveys clearly conveyed the challenges faced by patients trying to manage their HAE attacks with injectable on-demand treatments.
  • The resulting non-compliance with treatment guidelines may lead to poor clinical outcomes, even among patients receiving LTP,” said Andrew Crockett, Chief Executive Officer of KalVista.
  • “We believe the efficacy and safety data from our phase 3 trial for sebetralstat show a potential path forward to address these persisting unmet needs.”

The effect of new housing supply in structural models: a forecasting performance evaluation

Retrieved on: 
Sunday, February 4, 2024
BET, Section 2, Model, XT, CIT, LTV, Forecasting, Total, Bank, RT, Elasticity, GDP, Website, University of Chicago Press, Process control block, Fiscal, Reproduction, University, WTP, Johns Hopkins University Press, E32, Faculty, Writing, KMR, Monetary economics, Household, Root mean square, YT, GFC, Language, VAR, A6, Motivation, Growth, PLT, Hartman–Grobman theorem, Research, House, Observation, Friction, Section 4, Classification, Macroeconomic model, BAA, AP, Kálmán, Odyssean Wicca, Parameter, Blue chip, A5, HPT, Mark Gertler, Learning, Smets, Inflation, ECB, Q2, Trade, CE, Hit, SPF, Review of Economic Dynamics, ZBW, Kolasa, LTM, R21, Patient, Prior, Shock, Movement, ZT, Australasian, M1, Lens, Great, Nobuhiro, European Central Bank, Estimator, Policy, LTI, COVID-19, Attention, HP, Feedback, Goethe University Frankfurt, International Journal of Forecasting, Federal Reserve, Federal Reserve Bank, Behavior, Health, Blue Chip Economic Indicators, Inverse, Zero lower bound, The Blue, Journal of Applied Econometrics, Economic forecasting, Matrix, Economy, Federal, R31, LTP, Chinese Blackjack, WTI, CES, Sim, Bit, Section 5, Capital market, Quantitative Economics, Credit, Motion, Central bank, Journal of Political Economy, Political economy, Taylor & Francis, Journal of Monetary Economics, Act, Binning, CPT, DPT, Point, MCMC, RealTime, Literature, Metropolis–Hastings algorithm, ZLB, TFP, Research Papers in Economics, Del Negro, GBT, Communication, Kalman filter, Markov, Cycle, Business cycle, Eurozone, DFF, PDF, Filter, Medical classification, American Economic Journal, Demand shock, Comparison, Employment, KTEH, Cobb–Douglas production function, Nonprofit organization, Sampler, PTW, Par, Liquidity trap, Paper, Nominal interest rate, QT, Exercise, Monetary policy, RTD, Interest rate, A7, University of Cambridge, Control, Statistics, Posterior, Pressure, American Economic Review, E37, Financial intermediary, Social science, Basel II, Delphic, Depreciation, European Economic Review, HPD, Ai, Calendar, E17, Government, Journal of Econometrics, HTM, Freedom, LTE, Probability, Face, Calibration, Oxford University Press, New Keynesian economics, Sun, HH, Me, Uncertainty, FPI, Production, Dynamics, Handbook, Real estate
Key Points: 

    ATEC Announces Record Preliminary Revenue Results for 2023 and 2024 Revenue Guidance

    Retrieved on: 
    Monday, January 8, 2024
    Health Technology, Health, Surgery, Medical Devices, EOS, Growth, Webcast, Lateral, ATEC, LTP, PTP

    “Our conviction that good spine surgery is good business drove sector-leading growth again in 2023,” said Pat Miles, Chairman and Chief Executive Officer.

    Key Points: 
    • “Our conviction that good spine surgery is good business drove sector-leading growth again in 2023,” said Pat Miles, Chairman and Chief Executive Officer.
    • Leveraging 100% spine focus, we will continue to earn market share by distinguishing ATEC with information-integrated procedures that improve spine surgery outcomes.
    • The Company anticipates full-year 2024 total revenue of $595 million, reflecting growth of approximately 23% to 24% compared to the full-year 2023.
    • The Company will report fourth quarter and full-year 2023 financial results, and provide guidance for 2024 profitability, on Tuesday, February 27, 2024, after the market close.

    Philippine Department of Tourism's Love the Philippines Campaign Sets the Stage for Unforgettable Holiday Celebrations in San Francisco

    Retrieved on: 
    Wednesday, December 20, 2023
    Filipino Americans, Family, Smell, Culture, Partnership, Love Adventure, Philippines campaign, Taste, LTP, SAN, Love, Heart, Beauty, Golden Gate Bridge, Food, Social media, Paris Fashion Week, Tourism, Nightclub

    It became a bustling marketplace visited by the FilAm community and non-Filipinos alike who enjoyed shopping for their holiday gifts.

    Key Points: 
    • It became a bustling marketplace visited by the FilAm community and non-Filipinos alike who enjoyed shopping for their holiday gifts.
    • Elevating the Merkado Kultura experience, guests had the opportunity to step into the immersive Love the Philippines "Experience Rooms."
    • Love Fashion, Love the Philippines at the San Francisco Fashion Festival:
      Tourism Attache Soleil Tropicales took the stage at the San Francisco Fashion Festival to present the new Love the Philippines campaign to esteemed guests, inviting them to join the festivities on December 30th.
    • Love Adventure, Love the Philippines Motorcycle Ride:
      Thrill-seekers and motorcycle enthusiasts were invited to join the Love Adventure, Love the Philippines Motorcycle Ride across the iconic Golden Gate Bridge.

    KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update

    Retrieved on: 
    Thursday, December 7, 2023
    Biotechnology, Pharmaceutical, Health, Clinical Trials, NDA, LTP, Research, Food, D, ODS, Asthma, Patient, European, New Drug Application, FDA, American College, Conference, KALV, HAE, Pharmaceutical industry, Allergy

    (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.

    Key Points: 
    • (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the second fiscal quarter ended October 31, 2023.
    • The increase in R&D expenses during the quarter primarily reflects the ongoing Phase 3 KONFIDENT and KONFIDENT-S trials.
    • The increase in G&A expenses was primarily due to increases in employee-related expenses, commercial strategy and supply chain expenses.
    • The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.

    KalVista Pharmaceuticals Presents Data on HAE Attacks in Patients Receiving Long-Term Prophylaxis at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference

    Retrieved on: 
    Tuesday, October 24, 2023
    Biotechnology, Pharmaceutical, Health, Clinical Trials, HAE, Conference, Asthma, LTP, Patient, KALV, Hereditary angioedema, International Conference on Population and Development, Pharmaceutical industry

    KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks occurring in patients receiving long-term prophylaxis (LTP) treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (APAAACI) in Singapore.

    Key Points: 
    • KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the presentation of a novel analysis characterizing hereditary angioedema (HAE) attacks occurring in patients receiving long-term prophylaxis (LTP) treatments at the Asia Pacific Association of Allergy, Asthma and Clinical Immunology 2023 International Conference (APAAACI) in Singapore.
    • A systematic literature review of interventional and observational LTP studies revealed that although LTP yields significant reductions in HAE attack frequency, many patients continue to experience attacks in all anatomic locations, including potentially life-threatening laryngeal attacks.
    • “As highlighted in HAE clinical practice guidelines, the goal of LTP is to achieve full control of disease burden.
    • “Access to safe and effective on-demand therapy is essential for all people living with HAE, including those receiving LTP.